Aclaris’s pipeline features two lead assets: a TSLP antagonist aimed at inflammatory skin and airway diseases, and a small-molecule ITK inhibitor targeting T-cell mediated disorders. Both programs advanced through early development, positioning the company for pivotal clinical milestones.

The TSLP antagonist is slated for Phase II topline efficacy data in mid-2026, while the ITK inhibitor will report interim safety and biomarker results in late 2026. Additional exploratory cohorts and dose-escalation data are planned across both programs to optimize dosing ahead of larger trials.

These 2026 readouts are designed to de-risk the programs and provide proof-of-concept data that could attract external collaborators or licensing partners. Aclaris anticipates using the data to negotiate potential partnerships and secure funding for pivotal trials.